PROTAC Degradation Assay Patents: Leaders & Filing Trends 2026
A data-backed view of the PROTAC degradation activity assay patent landscape: who is filing, how fast the field is growing, and where the technology classes concentrate.
Filing growth = 2021 (3 records) → 2024 (22); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 88 records in scope (CR5), not the ranked leaders only.
What the PROTAC degradation assay patent record shows
Targeted protein degradation assay patents sit at the intersection of medicinal chemistry and analytical method claims: most records describe a degrader compound together with the assay used to demonstrate degradation activity, rather than an assay platform on its own. Across the 88 records in scope, the bulk of claim language lands in A61K (medicinal preparations) and A61P (therapeutic activity), with heterocyclic chemistry under C07D and peptide/protein claims under C07K forming the next tier. Dedicated testing and measurement classes — G01N and C12Q — appear in a minority of records, which signals that assay methodology is still frequently claimed as a dependent or supporting element rather than the primary invention.
Filing activity is recent and concentrated: the earliest records date to 2017, and the field did not accelerate until 2021 onward, peaking so far at 22 records in 2024. Because publication typically lags filing by roughly 18 months, the 2025 and 2026 figures in the trend understate actual filing activity and should not be read as a slowdown.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 88 records: how filing volume has moved year over year, and which IPC subclasses carry the claim language.
Filing trend, 2017-2026
Annual filings rose from 2 in 2017 to a peak of 22 in 2024, with the 2021-to-2024 span alone showing growth of +633% (3 to 22). 2025 and 2026 figures are still incomplete due to publication lag and should be read as provisional, not as a decline.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
IPC subclass composition
A61K and A61P each cover roughly seven in ten records, reflecting the field's grounding in degrader compound chemistry and therapeutic use. Assay-specific classes G01N and C12Q cover a much smaller share of the 88 records, and C12P (fermentation & enzymatic synthesis) is the thinnest class at 5.7%.
Shares are the percentage of the 88 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Targeted Protein Degradation: PROTAC Degradation Activity Assay Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about targeted protein degradation: protac degradation activity assay patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative recent filing
WO2026098644A1 — Targeted protein degrader and pharmaceutical composition thereof
The filing discloses a targeted protein degrader and its pharmaceutical composition, prepared to show significant degradation activity against a target protein. The degrader is proposed for use as the payload of an antibody-drug conjugate, using antibody targeting and antigen-mediated internalisation to achieve more effective and safer degradation of the target protein for treating target-protein-mediated diseases such as tumours.Filed by Beijing Synthetic Vaccine Biosciences Co., Ltd., published 2026-05-15.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | CN105085620A | 一种靶向泛素化降解Smad3的化合物 | 64 |
| 2 | CN106977584A | 靶向泛素化降解PLK1和BRD4蛋白的化合物及其应用 | 45 |
| 3 | WO2022161414A1 | 芳香化合物、含其的药物组合物及其应用 | 28 |
| 4 | WO2025083472A2 | Protac compounds binding KEAP1 ubiquitin ligase for targeted protein degradation | 13 |
| 5 | CN112062768A | 具有Aurora激酶降解活性的小分子及其制备方法和应用 | 9 |
| 6 | CN116648248A | 芳香化合物、含其的药物组合物及其应用 | 7 |
| 7 | CN115873018A | 苯并嘧啶和苯并三嗪类造血祖细胞激酶1降解剂及其应用 | 6 |
| 8 | CN113861213A | 一种具有STAT3降解活性的川楝素PROTAC化合物及其制备方法和应用 | 6 |
| 9 | CN114917359A | 针对细胞周期多时空分布抗癌靶点的PROTAC组合物 | 5 |
| 10 | US20210238224A1 | Method of constructing protac by using double targets | 5 |
Citation counts favour older records in a searched corpus; treat them as a signal of influence on the field rather than of current commercial relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and composition figures mean for filing strategy
Three patterns stand out once the assignee ranking, filing trend and IPC composition are read together.
No single assignee controls the field
The leading assignee holds 6 records out of 88, and the top 5 combined account for 26.1% of all records in scope. The top 10 combined reach 43.2%, meaning well over half the field is held by the remaining 49 ranked entrants, most with only one or two filings.
The field is young and still accelerating
Filings moved from 3 in 2021 to a peak of 22 in 2024, a +633% rise over three years. Because publication lags filing by around 18 months, the true 2025-2026 filing volume is still being reported and should not be read from the published counts alone.
Filing activity is heavily routed through China
China accounts for 60 of the 88 records, with WIPO (PCT), the United States and the EPO trailing well behind. Any freedom-to-operate check for this space needs to start with Chinese-language prior art rather than treating it as a secondary jurisdiction.
Assay methodology claims are the thinner layer
Compound and therapeutic-use classes (A61K, A61P, C07D, C07K) dominate the composition, while dedicated measurement and testing classes (G01N, C12Q) cover a smaller share of the 88 records. That gap is where assay-specific claim language is least crowded.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to targeted protein degradation: protac degradation activity assay patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Beth Israel Deaconess Medical Center | Icahn School of Medicine at Mount Sinai | 3 |
| Zhengzhou University | Institute of Materia Medica, Chinese Academy of Medical Sciences | 2 |
Only 2 co-assignee pairs appear in the dataset, the strongest linking a US medical centre pair and a China university-institute pair, each with 2-3 shared records. Collaborative filing is not yet a common pattern in this space.
Where to take this analysis
The figures above describe the field as filed. Turning them into a filing or freedom-to-operate decision means going deeper on specific claims and specific assignees.
Map claim language against your own compound class
Compare your degrader chemistry against the C07D and C07K claim clusters to see which structural scaffolds are already dense with prior art.
Run a claim comparison in EurekaTrack the long tail of single-filing entrants
With 59 ranked assignees and no dominant leader, new entrants surface every filing cycle; a standing watch catches them before a freedom-to-operate review does.
Set up a monitoring search in EurekaCheck the assay-specific white space
G01N and C12Q coverage sits well below the compound classes, suggesting method-of-testing claims are less contested than composition claims.
Explore assay claim gaps in EurekaCommon questions about PROTAC degradation assay patents
The dataset behind this landscape contains 88 published patent records matching PROTAC and targeted protein degradation assay claim language, filed between 2015 and the August 2026 data cut-off. Because publication lags filing by roughly 18 months, the true count of already-filed but not-yet-published applications is somewhat higher, particularly for 2025 and 2026. Most of these records combine a degrader compound claim with an assay or screening step used to demonstrate degradation activity, rather than claiming an assay method in isolation.
The assignee ranking covers 59 companies and research institutes, and it is not a top-50 or top-100 cut — it is the entire ranked field. The single leader holds 6 records, and the top 5 combined account for 26.1% of the 88 records in scope, which means no one organisation controls the space. A long tail of single- or double-filing entrants, many of them Chinese universities and research institutes, makes up the rest of the ranking.
It is growing, sharply. Annual filings rose from 3 in 2021 to a peak of 22 in 2024, a +633% increase over that three-year span, and 2024 is the most recent year that can be treated as a complete annual figure. The apparent dip in 2025 and 2026 is a publication-lag artefact, not a real slowdown, since patent publication typically trails the filing date by about 18 months.
The IPC composition data points toward assay methodology rather than compound chemistry. A61K and A61P, the medicinal-preparation and therapeutic-activity classes, each cover around seven in ten of the 88 records, while G01N (material analysis and testing) and C12Q (enzyme and DNA measurement) cover only 15.9% and 12.5% respectively. That gap suggests dedicated assay-method claims — as opposed to degrader-compound claims with an assay attached — are comparatively under-claimed.
China, by a wide margin. Of the 88 records in scope, 60 were filed through the China receiving office, compared with 13 through WIPO's PCT route, 8 in the United States and 5 through the EPO. Any freedom-to-operate or clearance search for PROTAC degradation assay claims that skips Chinese-language prior art is working from an incomplete picture of the field.
Research Targeted Protein Degradation: PROTAC Degradation Activity Assay Patent Landscape in depth with Eureka
Go past this page: query the whole targeted protein degradation: protac degradation activity assay patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.